|
Match
|
Document |
Document Title |
|
|
7537763 |
Anti-CD40 monoclonal antibody
An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.
|
|
|
7538195 |
Anti-IGF-I receptor antibody
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit...
|
|
|
7534430 |
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one...
|
|
|
7534427 |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially...
|
|
|
7534432 |
Methods of treating musculodegenerative disease with an antibody that binds growth differentiation factor-8
Growth differentiation factor-8 (GDF-8) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-8...
|
|
|
7534428 |
Antibodies to tumor necrosis factor receptors 6α and 6β
The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α &...
|
|
|
7531174 |
Cripto blocking antibodies and uses thereof
The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided....
|
|
|
7531633 |
Staphylococcus antibodies
A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of ...
|
|
|
7531175 |
Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules
The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The...
|
|
|
7531169 |
High affinity anti-human IgE antibodies
The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and...
|
|
|
7531177 |
Surface protein of leptospira
The invention relates to Leptospiral surface proteins, and the nucleic acid molecules which encode them. Various uses are described, including immunoprophylactic, diagnostic and therapeutic methods.
|
|
|
7531171 |
Antibodies to non-functional P2X7 receptor
The present invention provides antibodies that specifically bind to P2X 7 receptors and distinguish between function and non-functional P2X 7 receptors, pharmaceutical compositions and kits...
|
|
|
7527788 |
Desaturase antigen of Mycobacterium tuberculosis
Antibodies that bind to the M. tuberculosis Des protein are provided.
|
|
|
7527790 |
Methods of reducing bone absorption comprising administering an antibody that binds OBM
Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided....
|
|
|
7527791 |
Humanized anti-TGF-beta antibodies
Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles...
|
|
|
7527786 |
Methods for inhibiting the growth of cancer cells expressing PSCA
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade...
|
|
|
7524498 |
Human immunomodulatory monoclonal antibodies for the treatment of cancer
The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation...
|
|
|
7524501 |
Methods of treating an injury to, or disorder of, the eye involving photoreceptor proliferation by administering VEGF2 antibodies
The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal...
|
|
|
7521052 |
Methods for treating interleukin-6 related diseases
A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is...
|
|
|
7521432 |
Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging
Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.
|
|
|
7521047 |
Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
The present invention relates to polypeptide compositions which bind to cell surface epitopes and, in multivalent forms, cause or lead to the killing of cells including lymphoid tumor cells, and in...
|
|
|
7521051 |
Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those...
|
|
|
7521542 |
Humanized FcγRIIB-specific antibodies and methods of use thereof
The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention...
|
|
|
7517862 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods...
|
|
|
7517965 |
Non-neutralizing anti-aPC antibodies
The present invention provides anti-aPC antibodies that suppress the inactivation of activated protein C (aPC), and uses thereof. The present inventors screened anti-aPC antibodies, and succeeded...
|
|
|
7517963 |
Tumour necrosis factor binding ligands
The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified....
|
|
|
7517524 |
Immunointeractive molecules
The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothelial growth factor-B (VEGF-B) or its functional or structural...
|
|
|
7517967 |
Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting...
|
|
|
7517523 |
Anti-MIF antibodies
The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the...
|
|
|
7514077 |
Methods of antagonizing signal transduction in dorsal root ganglion cells with IL-31 antagonists
Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include...
|
|
|
7514079 |
Antibodies that specifically bind to neurokinin B
The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well...
|
|
|
7514078 |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or...
|
|
|
7514539 |
Epitope directed selection of antibodies to murine tissue factor
A tissue factor antibody which binds to non-human tissue factor and is useful as a surrogate in preclinical testing where the human therapeutic tissue factor candidate antibody does not interact...
|
|
|
7510707 |
PAR, a novel marker gene for breast and prostate cancers
The present invention relates to a gene selectively expressed in malignant cells and associated with the development of androgen resistance in prostate cancer. Levels of the gene, termed “PAR”...
|
|
|
7510712 |
Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7511122 |
Humanized and chimeric antibodies specific for lipoteichoic acid of GRAM positive bacteria
The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis...
|
|
|
7510713 |
Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7510710 |
Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a...
|
|
|
7510711 |
Methods for the treatment of cancer using anti-CD40 antibodies
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the...
|
|
|
7507408 |
Anti hepatitis C virus antibody and uses thereof
Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible...
|
|
|
7504106 |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
A method for treating patients with renal failure includes administering to them an effective amount of antibody or of a functional equivalent thereof to at least two of urea, creatinine, tumor...
|
|
|
7504105 |
Treatment using antibodies to cytokine receptor common gamma chain like
The present invention relates to a novel human gene encoding a polypeptide which is a member of the Cytokine Receptor family. More specifically, the present invention relates to a polynucleotide...
|
|
|
7504101 |
Methods for enhancing antigen-specific immune response using antibodies that bind OX-40
Compositions and methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells are disclosed, comprising administering to the mammal a...
|
|
|
7501498 |
Alpha-fetoprotein Immu31 antibodies and fusion proteins
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as...
|
|
|
7501496 |
Anti-OX40L antibodies
This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor...
|
|
|
7501247 |
Method of treating skin inflammation
Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17 and/or IL-23.
|
|
|
7501124 |
Methods of inducing T-cell non-responsiveness with anti-gp39 24-31 antibodies
Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which...
|
|
|
7498028 |
Preparation of spheres for diagnostic tests
The invention relates to surfactant-free reagent spheres useful for biological tests particularly those involving antigen/antibody reactions.
|
|
|
7498032 |
Methods for treating immune disorders or cancer with anti-CD40 antibodies
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the...
|
|
|
7498027 |
Methods of treatment using human tumor necrosis factor receptor TR17 antibodies
The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided...
|